7 results about "Infectious peritonitis" patented technology

This invention provides a saRNA vaccine for the prevention of feline infectious peritonitis (FIP). The saRNA vaccine is a composition comprising saRNA A and saRNA B. The assembly elements of the saRNA include: a 5′ UTR, replicases nsp1-nsp4, a subgenomic promoter, a Kozak sequence, nucleic acid sequence A or nucleic acid sequence B, a 3′ UTR, and a polyadenylated tail (polyA). The saRNA vaccine provided by this invention is effective for the immunization prophylaxis of FIP types I and II. Furthermore, based on the development of this vaccine, by replacing the coding sequences of different antigens, it can be extended to the development of vaccines for other coronaviruses or other veterinary pathogens, demonstrating significant technological transfer value and industrialization prospects.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The application relates to a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof, relates to the technical field of biology, and aims to provide a cat infectious peritonitis virus S protein receptor binding region monoclonal antibody and application thereof.The amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown in a sequence table SEQ ID NO.1, and the amino acid sequence of a light chain variable region is shown in a sequence table SEQ ID NO.2.The application adopts Western blot and IFA methods to identify the reactivity of MAb, and identifies an antigen epitope recognized by MAb.The antigen epitope is conservative in type I cat coronavirus, which indicates that the monoclonal antibody can recognize various type I FCoV strains, has broad spectrum, and is not accidentally directed to a single strain.The antigen epitope has no cross reaction with type II, which indicates that the specificity is high, can be used for distinguishing type I and type II infections, and has diagnostic application value.

This invention belongs to the field of biomedicine, specifically relating to a secretory self-assembling nanoparticle mRNA vaccine for feline infectious peritonitis and its application. First, this invention constructs a Ferritin fusion antigen by fusing the RBD or S1 fragment of the FIPV S protein with ferritin. Second, this invention constructs an mRNA encoding the aforementioned Ferritin fusion antigen. The mRNA is delivered into host cells via lipid nanoparticles (LNPs), where it is translated and expressed in the cytoplasm. The Ferritin fusion antigen then forms a nanoparticle structure within the cell using its natural self-assembly properties, eliminating the need for in vitro assembly steps. Compared to traditional nanoparticle vaccines, this method avoids steps such as in vitro induction expression, purification, and adjuvant addition, simplifying the production process, improving immunogenicity, reducing the risk of adverse drug reactions (ADE), and enhancing safety. Furthermore, it significantly improves humoral and cellular immunity.